Benzinga · Aug 10, 2026
B. Riley Securities Reiterates Buy on Zymeworks, Raises Price Target to $44
B. Riley Securities analyst Mayank Mamtani reiterates Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $40 to $44.
ZY
NASDAQ · ZYME
Zymeworks Inc.
Healthcare · Biotechnology
$28.67
Up+$2.10 (+7.90%)
Updated Aug 22, 2026, 11:57 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.88B
- P/E ratio
- -0.1
- Dividend yield
- 0.00%
- 52-week range
- $21.52 – $29.75
- Volume
- 836.38K
- Avg. volume
- 1.14M
Price performance
ZYME price history
1M range · 21 trading sessions · Daily adjusted prices
ZYME closed at $28.67 after 21 trading sessions, up 25.42% for the selected period.
- Last close
- $28.67
- Period change
- +25.42%
- Period low
- $21.81
- Period high
- $28.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $26.97 | $28.74 | $26.77 | $28.67 | 836.38K |
| Aug 20, 2026 | $27.08 | $27.16 | $26.235 | $26.57 | 498.75K |
| Aug 19, 2026 | $27.12 | $27.8326 | $26.365 | $27.21 | 845.21K |
| Aug 18, 2026 | $25.35 | $26.35 | $25.31 | $26.07 | 650.17K |
| Aug 17, 2026 | $25.01 | $25.80 | $24.94 | $25.31 | 442.4K |
| Aug 14, 2026 | $25.62 | $25.73 | $24.89 | $25.12 | 332.6K |
| Aug 13, 2026 | $25.27 | $25.99 | $24.96 | $25.76 | 664.68K |
| Aug 12, 2026 | $24.20 | $25.09 | $23.94 | $24.93 | 563.64K |
| Aug 11, 2026 | $24.65 | $24.93 | $24.17 | $24.32 | 461.24K |
| Aug 10, 2026 | $23.63 | $24.195 | $23.47 | $24.16 | 819.97K |
| Aug 7, 2026 | $24.10 | $24.76 | $23.18 | $23.54 | 578.11K |
| Aug 6, 2026 | $23.50 | $23.84 | $23.10 | $23.13 | 673.71K |
| Aug 5, 2026 | $23.10 | $23.91 | $22.81 | $23.50 | 488.4K |
| Aug 4, 2026 | $22.41 | $23.435 | $21.97 | $22.79 | 419.79K |
| Aug 3, 2026 | $21.95 | $22.14 | $21.52 | $21.81 | 398.34K |
| Jul 31, 2026 | $22.745 | $22.745 | $21.80 | $21.94 | 375.12K |
| Jul 30, 2026 | $22.02 | $23.00 | $21.90 | $22.71 | 402.87K |
| Jul 29, 2026 | $22.66 | $22.96 | $21.90 | $22.01 | 340.49K |
| Jul 28, 2026 | $23.20 | $23.50 | $22.35 | $22.61 | 358.04K |
| Jul 27, 2026 | $23.07 | $23.585 | $22.99 | $23.00 | 259.3K |
| Jul 24, 2026 | $23.32 | $23.69 | $22.72 | $22.86 | 272.38K |
Latest ZYME news
The latest Smart Investors Daily articles mentioning ZYME.
Stock researchCompany · Overview
ZYME research
Overview
Company profile and research snapshot.
Company profile
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $32.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | B. Riley Securities | Buy | — |
| Aug 7, 2026 | Wells Fargo | Overweight | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 7, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $40
Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $37 to $40.
Benzinga · Aug 7, 2026
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $32
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $31 to $32.
Benzinga · Aug 5, 2026
HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $51
HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $46 to $51.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
